 TOULOUSE, France LAKELAND, Mich.BUSINESS WIRERegulatory News: ABIONYX Pharma FR0012616852 ABNX PEA PME eligible, a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today reported that the pilot Phase 2a clinical trial evaluating CER-001, the only natural recombinant apoA-I, as a treatment for septic patients at ... ABIONYX Pharma Reports Positive Results from Phase 2a Pilot ... 